AMD-Research Promising

Age-related macular degeneration impacts the lives of millions of people around the globe. Vision loss is caused by inflammation in the eye that leads to excessive growth of blood vessels in the retina. Current therapies to slow the process are anti-VEGF therapies such as Regeneron and Bayer's Eylea.

A new study shows that Sanofi and Regeneron's drug Dupixent could be useful in treating AMD. The research team contends that immune molecule interleukin-4 (IL-4) and its receptor—which Dupixent inhibits—may be promising for those living with macular degeneration. IL-4 is known to inhibit the formation of new blood vessels.

"Our results show that IL-4 plays a crucial role in excessive blood-vessel growth by recruiting bone marrow cells that aid this growth to the lesion in the eye," said Takashi Baba, the study's co-first author.

If you require help with vision impairment or blindness, then please contact SDCB.

Could Sanofi and Regeneron's Dupixent also treat age-related macular degeneration?